慢性乙型肝炎合并非酒精性脂肪性肝病临床研究进展*

doi:10.3969/j.issn.1672-5069.2019.01.039

Abstract

Abstract: The incidence rate of non-alcoholic fatty liver disease （NAFLD） with concurrent chronic hepatitis B （CHB） is increasing gradually. We will compare serum indexes, image and pathology characteristics among patients with NAFLD,CHB and NAFLD concurrent with CHB. The virus and host are both involved in the pathogenesis of steatosis. We will discuss all the above questions.

Key words: Chronic hepatitis B, Non-alcoholic fatty liver disease, Pathogenesis, Therapy

Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.

References

[1] European association for the study of the liver. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370.
[2] Abd ElKader SM,El Den Ashmawy EM. Non-alcoholic fatty liver disease:The diagnosis and management.World J Hepatol,2015,7(6):846.
[3] Wang MM,Wang GS,Shen F,et al.Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci,2014,59(10):2571-2579.
[4] Liang J,Cai W,Han T,et al.The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease.Medicine,2016,95(52):e5763.
[5] Machado M V,Oliveira A G,Cortez-Pinto H.Hepatic steatosis in hepatitis B virus infected patients:meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol,2011,26(9):1361-1367.
[6] Liu X,Shen Z,Zhang H,et al.Interleukin-21 is associated with early antiviral response in patients with hepatitis B e antigen-positive chronic hepatitis B and nonalcoholic fatty liver disease. J Interferon Cytokine Res,2016,36(6):367.
[7] Yuki H,Haga YJ,Tatsuo S,et al.Nonalcoholic fatty liver disease and hepatic cirrhosis:comparison with viral hepatitis-associated steatosis. World J Gastroenterol,2015,21(46):12989.
[8] Chan A W,Wong G L,Chan H Y,et al.Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol,2017,32(3):667.
[9] Cheng Y L,Wang Y J,Kao W Y,et al.Inverse association between hepatitis B virus infection and fatty liver disease:a large-scale study in populations seeking for check-up. Plos One,2013,8(8):e72049.
[10] 施军平,范建高,武瑞, 等. 慢性乙型肝炎患者肝细胞脂肪变的发生率及其危险因素分析.中华肝脏病杂志,2008,16(7):519-523.
[11] 宓余强,刘勇钢,徐亮,等. 慢性乙型肝炎合并肝脂肪变的临床与病理学特征分析. 中华肝脏病杂志,2014,17(6):817-820.
[12] Nau AL,Soares JC,Shiozawa MB,et al.Clinical and laboratory characteristics associated with dyslipidemia and liver steatosis in chronic HBV carriers. Rev Soc Bras De Med Trop,2014,47(2):158.
[13] Ceylan B,Arslan F,Batirel A,et al.Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir. Turk J Gastroenterol,2015,27(1):42.
[14] Zhu L Y,Wang Y G,Wei L Q,et al.The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease. Drug De Devel Ther,2016,10:2739-2744.
[15] Chen J D.Sonographic fatty liver and hepatitis B virus carrier status:Synergistic effect on liver damage in Taiwanese adults. World J Gastroenterol,2007,13(12):1805.
[16] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会. 非酒精性脂肪性肝病诊疗指南(2018年版). 实用肝脏病杂志. 2018,21(2):177-186.
[17] Weinstein A A,Kallman P J,Stepanova M,et al.Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics,2011,52(2):127-132.
[18] 中华医学会传染病与,寄生虫病学分会,肝病学分会. 病毒性肝炎防治方案. 中华内科杂志,2001,40(1):324-329.
[19] Yeom S K,Chang H L,Sang H C,et al.Prediction of liver cirrhosis,using diagnostic imaging tools. World J Hepatol,2015,7(17):2069.
[20] 贺文,马大庆,冯捷,等. CT定量诊断脂肪肝的临床研究. 中华放射学杂志,2001,35(11):829-831.
[21] Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int,2017,37 Suppl 1:85.
[22] Ballestri S,Nascimbeni F,Baldelli E,et al.Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism,2017,72:57-65.
[23] Hytiroglou P.17-Hepatitis B. Prac Hepatic Pathol,2011,33(6):215-224.
[24] Lefkowitch J H.Advances in hepatobiliary pathology:update for 2010.Clin Liver Dis,2010,14(4):747.
[25] Seto W K,Yuen M F.Nonalcoholic fatty liver disease in Asia:emerging perspectives. J Gastroenterol,2017,52(2):164.
[26] Wang CC,Kao JH.Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease:a cohort study. Hepatology,2016,65(3):828.
[27] Nascimento A C,Maia D R,Neto S M,et al.Nonalcoholic fatty liver disease in chronic hepatitis B and C patients from western Amazon. Int J Hepatol,2012(4):695950.
[28] Negro F.Hepatitis C virus-induced steatosis:an overview. Dig Dis,2010,28(1):294.
[29] 江萃英,曾维琼,陈压西,等. 乙型肝炎病毒对肝脂肪变患者肝细胞固醇调节元件结合蛋白表达的影响.中华肝脏病杂志,2011,19(8):608-613.
[30] Kyeongjin K,Hwan K K,Jaehun C.Hepatitis B virus X protein impairs hepatic insulin signaling through degradation of IRS1 and induction of SOCS3. Plos One,2010,5(3):e8649.
[31] 陈娟,沈薇,程文会. 乙型肝炎病毒X蛋白对HepG2细胞脂代谢相关基因表达的影响. 中华肝脏病杂志,2011,19(10):768-773.
[32] Cheng Y L,Wang Y J,Kao W Y,et al.Inverse association between hepatitis B virus infection and fatty liver disease:a large-scale study in populations seeking for check-up. Plos One,2013,8(8):e72049.
[33] 施军平,范建高,武瑞,等. 慢性乙型肝炎患者肝细胞脂肪变的发生率及其危险因素分析. 中华肝脏病杂志,2008,16(7):519-523.
[34] Zheng R D,Chen J N,Zhuang Q Y,et al.Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis. Int J Med Sci,2013,10(5):641-646.
[35] Zhang R N,Qin P,Zheng Z,et al.Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic fatty liver disease by Toll-Like receptor 4-Mediated innate immune response. Hepat Mon,2015,15(5):e27909.
[36] Pan Q,Zhang R N,Wang Y Q,et al.Linked PNPLA3 polymorphisms confer susceptibility tononalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. World J Gastroenterol,2015,21(28):8605-8614.
[37] 陆璐,柳银兰,杨文君,等. 慢性乙型肝炎病毒携带合并非酒精性脂肪性肝病小鼠模型建立与观察.中华实验和临床病毒学杂志,2013,27(5):332-335.
[38] Chen Y,Fan C,Chen Y,et al.Effect of hepatic steatosis on the progression of chronic hepatitis B:A prospective cohort and in vitro study. Oncotarget,2017,8(35):58601-58610.

Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[3]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[4]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[5]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[6]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[7]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[8]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[9]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[10]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[11]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[12]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[13]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[14]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[15]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.